Santen Pharmaceutical Co., Ltd.

Symbol: SNPHY

PNK

9.41

USD

Market price today

  • 18.3944

    P/E Ratio

  • 0.0004

    PEG Ratio

  • 3.43B

    MRK Cap

  • 0.00%

    DIV Yield

Santen Pharmaceutical Co., Ltd. (SNPHY) Stock Price & Analysis

Shares Outstanding

364.74M

Gross Profit Margin

0.61%

Operating Profit Margin

0.14%

Net Profit Margin

0.09%

Return on Assets

0.06%

Return on Equity

0.09%

Return on Capital Employed

0.13%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Takeshi Ito
Full-time employees:4144
City:Osaka
Address:Grand Front Osaka Tower A
IPO:2011-08-31
CIK:

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

General Outlook

In simple terms, Santen Pharmaceutical Co., Ltd. has 364.737 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.606% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.143%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.092%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.065% return, is a testament to Santen Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Santen Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.092%. Furthermore, the proficiency of Santen Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.128% return on capital employed.

Stock Prices

Santen Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $9.62, while its low point bottomed out at $9.09. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Santen Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing SNPHY liquidity ratios reveals its financial health of the firm. The current ratio of 245.64% gauges short-term asset coverage for liabilities. The quick ratio (184.06%) assesses immediate liquidity, while the cash ratio (89.71%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio245.64%
Quick Ratio184.06%
Cash Ratio89.71%

Profitability Ratios

SNPHY profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 13.03% underscores its earnings before tax deductions. The effective tax rate stands at 29.65%, revealing its tax efficiency. The net income per EBT, 70.46%, and the EBT per EBIT, 91.06%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 14.31%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin13.03%
Effective Tax Rate29.65%
Net Income per EBT70.46%
EBT per EBIT91.06%
EBIT per Revenue14.31%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.46, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 355.64% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding184
Days of Inventory Outstanding144
Operating Cycle246.43
Days of Payables Outstanding138
Cash Conversion Cycle108
Receivables Turnover3.56
Payables Turnover2.64
Inventory Turnover2.54
Fixed Asset Turnover4.41
Asset Turnover0.71

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 192.60, and free cash flow per share, 162.21, depict cash generation on a per-share basis. The cash per share value, 235.72, showcases liquidity position. A payout ratio of 0.43 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.23, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share192.60
Free Cash Flow per Share162.21
Cash per Share235.72
Payout Ratio0.43
Operating Cash Flow Sales Ratio0.23
Free Cash Flow to Operating Cash Flow Ratio0.84
Cash Flow Coverage Ratio2.03
Capital Expenditure Coverage Ratio6.34
Dividend Paid and Capex Coverage Ratio3.01
Dividend Payout Ratio0.03

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 7.86%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.11, we discern the balance between debt and equity financing. The long-term debt to capitalization, 10.12%, and total debt to capitalization, 10.12%, ratios shed light on its capital structure. An interest coverage of 20.13 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio7.86%
Debt Equity Ratio0.11
Long Term Debt to Capitalization10.12%
Total Debt to Capitalization10.12%
Interest Coverage20.13
Cash Flow to Debt Ratio2.03
Company Equity Multiplier1.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 720.24, provides a glimpse into top-line earnings distributed across each share. Net income per share, -38.58, reflects the portion of profit attributed to each share. The book value per share, 758.81, represents the net asset value distributed per share, while the tangible book value per share, 489.40, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share720.24
Net Income Per Share-38.58
Book Value Per Share758.81
Tangible Book Value Per Share489.40
Shareholders Equity Per Share758.81
Interest Debt Per Share84.54
Capex Per Share-63.47

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 6.67%, indicates top-line expansion, while the gross profit growth, 3.44%, reveals profitability trends. EBIT growth, 177.82%, and operating income growth, 177.82%, offer insights into operational profitability progression. The net income growth, 298.51%, showcases bottom-line expansion, and the EPS growth, 298.13%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth6.67%
Gross Profit Growth3.44%
EBIT Growth177.82%
Operating Income Growth177.82%
Net Income Growth298.51%
EPS Growth298.13%
EPS Diluted Growth298.42%
Weighted Average Shares Growth0.08%
Weighted Average Shares Diluted Growth0.02%
Dividends per Share Growth7.12%
Operating Cash Flow Growth18.64%
Free Cash Flow Growth-32.00%
10-Year Revenue Growth per Share135.96%
5-Year Revenue Growth per Share20.33%
3-Year Revenue Growth per Share15.59%
10-Year Operating CF Growth per Share388.67%
5-Year Operating CF Growth per Share9.25%
3-Year Operating CF Growth per Share42.21%
10-Year Net Income Growth per Share73.85%
5-Year Net Income Growth per Share-21.53%
3-Year Net Income Growth per Share-13.43%
10-Year Shareholders Equity Growth per Share115.65%
5-Year Shareholders Equity Growth per Share20.04%
3-Year Shareholders Equity Growth per Share17.87%
10-Year Dividend per Share Growth per Share49.45%
5-Year Dividend per Share Growth per Share15.48%
3-Year Dividend per Share Growth per Share15.18%
Receivables Growth3.75%
Inventory Growth-10.67%
Asset Growth14.32%
Book Value per Share Growth9.63%
R&D Expense Growth9.39%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 414,880,040,923.493, captures the company's total value, considering both debt and equity. Income quality, -2.48, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.34, gauges operational efficiency, while the research and development to revenue, 10.14%, highlights investment in innovation. The ratio of intangibles to total assets, 22.87%, indicates the value of non-physical assets, and capex to operating cash flow, -66.19%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value414,880,040,923.493
Income Quality-2.48
Sales General and Administrative to Revenue0.34
Research and Development to Revenue10.14%
Intangibles to Total Assets22.87%
Capex to Operating Cash Flow-66.19%
Capex to Revenue-8.81%
Capex to Depreciation-142.55%
Graham Number811.63
Return on Tangible Assets-4.60%
Graham Net Net79.73
Working Capital123,822,000,000
Tangible Asset Value196,988,000,000
Net Current Asset Value85,444,000,000
Average Receivables103,408,000,000
Average Payables43,065,000,000
Average Inventory38,246,500,000
Days Sales Outstanding140
Days Payables Outstanding145
Days of Inventory On Hand127
ROIC-2.42%
ROE-0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.71, and the price to book ratio, 1.71, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.74, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 9.17, and price to operating cash flows, 7.49, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.71
Price to Book Ratio1.71
Price to Sales Ratio1.74
Price Cash Flow Ratio7.49
Enterprise Value Multiple9.70
Price Fair Value1.71
Price to Operating Cash Flow Ratio7.49
Price to Free Cash Flows Ratio9.17
Price to Tangible Book Ratio1.49
Enterprise Value to Sales1.49
Enterprise Value Over EBITDA32.04
EV to Operating Cash Flow11.17
Earnings Yield-3.42%
Free Cash Flow Yield2.88%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Santen Pharmaceutical Co., Ltd. (SNPHY) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 18.394 in 2024.

What is the ticker symbol of Santen Pharmaceutical Co., Ltd. stock?

The ticker symbol of Santen Pharmaceutical Co., Ltd. stock is SNPHY.

What is company IPO date?

IPO date of Santen Pharmaceutical Co., Ltd. is 2011-08-31.

What is company current share price?

Current share price is 9.410 USD.

What is stock market cap today?

The market cap of stock today is 3430719622.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 4144.